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Immunotherapy for Sepsis — A New Approach  
against an Ancient Foe
Richard S. Hotchkiss, M.D., and Steven Opal, M.D.
Septic shock is traditionally viewed as an exces-
sive systemic inflammatory reaction to invasive 
microbial pathogens, yet efforts to improve the 
outcome of patients with sepsis by means of in-
hibitors of proinflammatory cytokines and media-
tors have been unsuccessful. Occasionally, patients 
present with an exaggerated systemic inflamma-
tory response to highly virulent pathogens (such 
as in cases of meningococcemia) and rapidly 
succumb. However, the vast majority of patients 
with sepsis survive the initial insult, only to end 
up in the intensive care unit with sepsis-induced 
multiorgan dysfunction days or weeks later. Sepsis-
induced immunosuppression is increasingly rec-
ognized as the overriding immune dysfunction 
in these vulnerable patients.1
The clinical relevance of this immunosup-
pressed state is evidenced by the frequent occur-
rence of infection with relatively avirulent and 
often multidrug-resistant bacterial, viral, or fungal 
pathogens such as species of stenotrophomonas, 
acinetobacter, candida, pseudomonas, enterococ-
cus, and cytomegalovirus. In light of progressive 
antimicrobial resistance and the paucity of new 
antimicrobial agents entering the developmental 
pipeline, the care of patients with sepsis is in-
creasingly challenging.2 Sepsis can be considered 
to represent a race between the pathogens and 
the host immune response; pathogens seek an 
advantage by incapacitating various aspects of 
host defenses. For example, they induce the apop-
totic depletion of immune effector cells, suppress 
the expression of major-histocompatibility-com-
plex class II molecules, increase expression of 
negative costimulatory molecules, increase anti-
inflammatory cytokines, and augment levels of 
regulatory T cells and myeloid-derived suppres-
sor cells (Fig. 1). The prevention of sepsis-induced 
immunosuppression, or its treatment if it occurs, 
is a research priority.
A recent study by Said and colleagues3 pro-
vides insights into the molecular mechanisms 
that underlie immune depression following sus-
tained inflammation, such as occurs in patients 
with either chronic viral infections or protract-
ed sepsis. These investigators studied a critical 
monocyte–macrophage protein known as pro-
grammed death 1 (PD-1), which is found in pa-
tients infected with the human immunodefi-
ciency virus (HIV). PD-1, a negative costimulatory 
molecule expressed on immune effector cells, is 
up-regulated along with its cognate ligand PD-L1 
(also expressed on effector cells) during chronic 
HIV infection. Said and colleagues found that 
microbial mediators translocate across the intes-
tinal epithelium in chronic HIV-induced inflam-
mation and are recognized by toll-like receptors. 
Persistent activation of the innate immune sys-
tem by these intestinally derived microbial prod-
ucts up-regulates the expression of PD-1 and 
PD-L1 on various immune cells.
PD-1 impairs immunity by inducing apopto-
sis, increasing production of interleukin-10 (a key 
antiinflammatory cytokine increased in sepsis), 
preventing T-cell proliferation, and causing T cells 
to become nonresponsive (“exhausted”). Said and 
colleagues described a new mechanism by which 
the interaction between PD-1 and PD-L1 induces 
immunosuppression in patients with HIV. They 
found that PD-1 activation results in the increased 
production of interleukin-10 by monocytes from 
persons infected with HIV. Moreover, the PD-1–
induced inhibition of CD4 T cells was itself in-
hibited by the blocking of the interleukin-10 re-
ceptor. Thus, PD-1 affects immunosuppression 
through its effect on interleukin-10 expression. 
These results suggest that blocking PD-1 may 
improve the prognosis of patients with any of a 
variety of chronic infections. These findings are 
consistent with the improved survival in mice 
with fungal infections, and in mice with bacte-
rial sepsis, in which PD-1 was inhibited.4
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Figure 1. Reversal of Immunosuppression in Sepsis.
In many cases of sepsis, the immune system fails to eradicate the infectious pathogens, and a prolonged phase of sepsis-induced immu-
nosuppression begins, characterized by a failure to eradicate the primary infection and by development of secondary nosocomial infec-
tions. This immunosuppression is mediated by multiple mechanisms, including massive apoptosis-induced depletion of lymphocytes 
and dendritic cells, decreased expression of the cell-surface antigen–presenting complex HLA-DR, and increased expression of the nega-
tive costimulatory molecules programmed death 1 (PD-1), cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4), and B- and T-lympho-
cyte attenuator (BTLA) and their corresponding ligands (e.g., PD-1 ligand [PD-L1]). Furthermore, the numbers of regulatory T cells and 
myeloid-derived suppressor cells (MDSCs) are increased, and there is a shift from a phenotype of inflammatory type 1 helper T (Th1) 
cells to an antiinflammatory phenotype of type 2 helper T (Th2) cells characterized by the production of interleukin-10. The net result is 
a severely compromised innate and adaptive immune system with poorly functional “exhausted” CD8 and anergic CD4 T cells. Targets 
of potential immunotherapeutic approaches (shown in red) include agents that block apoptosis, block negative costimulatory molecules, 
decrease the level of antiinflammatory cytokines, increase HLA-DR expression, and reactivate “exhausted” or anergic T cells. FLT-3L 
 denotes Fms-related tyrosine kinase 3 ligand, GM-CSF granulocyte–macrophage colony-stimulating factor, LFA-1 lymphocyte function–
associated antigen 1, and TNF-α tumor necrosis factor α.
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Although it is possible that immunostimula-
tory therapy exacerbates the hyperinflammatory 
phase of sepsis or induces autoimmunity, clinical 
trials of interferon-γ, a potent immunostimula-
tory agent, and granulocyte colony-stimulating 
factor and granulocyte–macrophage colony-stim-
ulating factor (GM-CSF) in patients with various 
systemic inflammatory states did not elicit un-
bridled inflammatory reactions. Most patients 
with refractory sepsis are so severely immuno-
suppressed that the development of hyperin-
flammation or autoimmunity is unlikely.
To prevent the extensive apoptosis-induced 
depletion of immune effector cells in patients 
with sepsis, one potential strategy is use of the 
antiapoptotic, immunostimulatory cytokines in-
terleukin-7 and interleukin-15; both agents have 
shown efficacy in models of infection, including 
sepsis. These cytokines, in preventing cell death, 
diminish the immunosuppressive effect on phag-
ocytic cells (which are relieved from disposing 
of increased numbers of apoptotic cells). Inter-
leukin-7 also restores the effector function of 
lymphocytes and improves lymphocyte migration 
by increasing the activity of integrins. Interleu-
kin-7 is currently in clinical trials to treat cancer 
and infection with hepatitis C virus and HIV.
In the future, immunotherapy will probably 
be tailored to the individual patient on the basis 
of specific laboratory or clinical findings. For 
example, a recent trial of GM-CSF to treat sepsis 
tested the effect only on patients in whom mono-
cyte HLA-DR expression was significantly de-
pressed.5 Flow-cytometric studies quantitating 
the level of expression of negative costimulatory 
molecules (such as PD-1 and PD-L1) on leuko-
cytes, or rapid whole-blood stimulation assays 
of cytokine secretion, could be used to guide 
immunotherapeutic decisions. Patients with cyto-
megalovirus infection or reactivation of herpes 
simplex virus type 1 and those with sepsis due 
to infection with opportunistic pathogens (such 
as stenotrophomonas or acinetobacter) are good 
candidates for immunoenhancing therapy.
An old saying goes, “Desperate diseases are 
cured by desperate means or not at all.” Trials 
of immunostimulatory agents should be under-
taken, with close monitoring of innate and 
adaptive immune function, in patients with de-
monstrable immunosuppression. Many potential-
ly beneficial immunomodulatory agents (Fig. 1) 
are currently in clinical trials for other indica-
tions and have reasonable safety profiles. We 
speculate that such approaches will have wide-
ranging effects and could represent a major ad-
vance in the field of infectious disease.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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